AssetMark Inc
AXSM icon

AssetMark Inc’s Axsome Therapeutics AXSM Stock Holding History

AssetMark Inc’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$911K Buy
4,939
+3,680
+292% +$801K ﹤0.01% 1109
2026
Q2 		$308K Buy
1,259
+77
+7% +$16.7K ﹤0.01% 1329
2026
Q1 		$200K Buy
1,182
+79
+7% +$13.6K ﹤0.01% 1354
2025
Q4 		$201K Sell
1,103
-150
-12% -$20.9K ﹤0.01% 1307
2025
Q3 		$152K Buy
1,253
+129
+11% +$14.5K ﹤0.01% 1328
2025
Q2 		$117K Buy
1,124
+137
+14% +$14.5K ﹤0.01% 1338
2025
Q1 		$115K Buy
987
+376
+62% +$42.8K ﹤0.01% 1246
2024
Q4 		$51.7K Buy
+611
New +$56.2K ﹤0.01% 1416

Other funds holding AXSM

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
M&G plc
M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return

AssetMark Inc's AXSM Position: Q3 2026 in Review

AssetMark Inc increased its Axsome Therapeutics (AXSM) stake by 292% in Q3 2026, buying an estimated $801K and bringing the position to 4,939 shares worth $911K. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

AssetMark Inc first reported a position in AXSM in Q4 2024 and has held it in 8 quarters since. 159 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • AssetMark Inc held 4,939 shares of Axsome Therapeutics worth $911K as of Q3 2026.
  • AssetMark Inc bought 3,680 Axsome Therapeutics shares in Q3 2026, an estimated $801K.
  • Axsome Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1109 holding.
  • AssetMark Inc first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • 159 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.